Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Results of Operations and Financial Condition

Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Results of Operations and Financial Condition
Item 2.02   Results of Operations and Financial Condition.

On August 14, 2019, Heat Biologics, Inc., a Delaware corporation (the “Registrant”) issued a press release that included financial information for its quarter ended June 30, 2019. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K. The information contained in the press release is being furnished to the Securities and Exchange Commission (the “Commission”) and shall not be deemed incorporated by reference into any of the Registrant’s registration statements or other filings with the Commission.

Item 9.01   Financial Statements and Exhibits.

The following exhibit is filed with this Current Report on Form 8-K:

  


HEAT BIOLOGICS, INC. Exhibit
EX-99.1 2 htbx_ex99z1.htm PRESS RELEASE Press Release   EXHIBIT 99.1 Heat Biologics Reports Second Quarter 2019 Results and Provides Corporate Update Completed enrollment of Phase 2 non-small cell lung cancer trial; on track to report top line data later this year Received FDA clearance of IND application for Phase 1 trial of HS-130 in combination with HS-110 for patients with advanced solid tumors refractory to standard of care DURHAM,…
To view the full exhibit click here

Story continues below

About Heat Biologics, Inc. (NASDAQ:HTBX)

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

An ad to help with our costs